Myriad Genetics Inc (NASDAQ:MYGN)

21.25
Delayed Data
As of May 25
 -0.09 / -0.42%
Today’s Change
18.98
Today|||52-Week Range
36.95
-23.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.8B

Company Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:

Employees

Shareholders

Individual stakeholders7.99%
Mutual fund holders52.62%
Other institutional48.12%

Top Executives

Paul J. DiazPresident, Chief Executive Officer & Director
Nicole LambertChief Operating Officer
R. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VP
Dale MuzzeyChief Scientific Officer
Kevin R. HaasChief Technology Officer